Remedy Entertainment Oyj Statistics
Total Valuation
HEL:REMEDY has a market cap or net worth of EUR 204.40 million. The enterprise value is 197.87 million.
Important Dates
The last earnings date was Tuesday, November 3, 2026.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HEL:REMEDY has 13.59 million shares outstanding. The number of shares has decreased by -0.04% in one year.
| Current Share Class | 13.59M |
| Shares Outstanding | 13.59M |
| Shares Change (YoY) | -0.04% |
| Shares Change (QoQ) | +0.61% |
| Owned by Insiders (%) | 27.65% |
| Owned by Institutions (%) | 18.77% |
| Float | 9.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 35.20 |
| PS Ratio | 2.48 |
| PB Ratio | 3.60 |
| P/TBV Ratio | 4.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 47.25 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.40 |
| EV / EBITDA | 10.88 |
| EV / EBIT | 14.42 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.10, with a Debt / Equity ratio of 0.32.
| Current Ratio | 2.10 |
| Quick Ratio | 2.10 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 1.00 |
| Debt / FCF | n/a |
| Interest Coverage | 8.75 |
Financial Efficiency
Return on equity (ROE) is -4.42% and return on invested capital (ROIC) is 29.00%.
| Return on Equity (ROE) | -4.42% |
| Return on Assets (ROA) | 8.99% |
| Return on Invested Capital (ROIC) | 29.00% |
| Return on Capital Employed (ROCE) | 18.37% |
| Weighted Average Cost of Capital (WACC) | 9.97% |
| Revenue Per Employee | 211,571 |
| Profits Per Employee | -6,526 |
| Employee Count | 378 |
| Asset Turnover | 0.86 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -275,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.08% in the last 52 weeks. The beta is 1.09, so HEL:REMEDY's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | +10.08% |
| 50-Day Moving Average | 17.30 |
| 200-Day Moving Average | 15.15 |
| Relative Strength Index (RSI) | 30.92 |
| Average Volume (20 Days) | 14,978 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HEL:REMEDY had revenue of EUR 79.97 million and -2.47 million in losses. Loss per share was -0.18.
| Revenue | 79.97M |
| Gross Profit | 72.66M |
| Operating Income | 13.31M |
| Pretax Income | -2.74M |
| Net Income | -2.47M |
| EBITDA | 16.30M |
| EBIT | 13.31M |
| Loss Per Share | -0.18 |
Full Income Statement Balance Sheet
The company has 24.12 million in cash and 17.59 million in debt, with a net cash position of 6.54 million or 0.48 per share.
| Cash & Cash Equivalents | 24.12M |
| Total Debt | 17.59M |
| Net Cash | 6.54M |
| Net Cash Per Share | 0.48 |
| Equity (Book Value) | 55.15M |
| Book Value Per Share | 4.06 |
| Working Capital | 27.09M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 4.20 million and capital expenditures -4.45 million, giving a free cash flow of -250,000.
| Operating Cash Flow | 4.20M |
| Capital Expenditures | -4.45M |
| Depreciation & Amortization | 2.99M |
| Net Borrowing | -1.44M |
| Free Cash Flow | -250,000 |
| FCF Per Share | -0.02 |
Full Cash Flow Statement Margins
Gross margin is 90.85%, with operating and profit margins of 16.64% and -3.08%.
| Gross Margin | 90.85% |
| Operating Margin | 16.64% |
| Pretax Margin | -3.43% |
| Profit Margin | -3.08% |
| EBITDA Margin | 20.38% |
| EBIT Margin | 16.64% |
| FCF Margin | n/a |
Dividends & Yields
HEL:REMEDY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.04% |
| Shareholder Yield | 0.04% |
| Earnings Yield | -1.21% |
| FCF Yield | -0.13% |
Dividend Details Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Analyst Forecast
The average price target for HEL:REMEDY is 21.00, which is 39.63% higher than the current price. The consensus rating is "Buy".
| Price Target | 21.00 |
| Price Target Difference | 39.63% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 24.86% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HEL:REMEDY has an Altman Z-Score of 4.41 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.41 |
| Piotroski F-Score | 4 |